

**Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208(b)(3)
Particular Matter Waivers**

Name: Maha Hussain, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date(s): May 30, 2008

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: New Drug Application (NDA) 022-291, Promacta (eltrombopag olamine), for the proposed indication for short-term treatment of previously-treated patients with chronic idiopathic thrombocytopenic purpura (ITP) to increase platelet counts and reduce or prevent bleeding. Promacata was originally developed by Ligand Pharmaceuticals Inc., in collaboration agreement with GlaxoSmithKline, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208(b)(3).

Type of Interest	Involvement	Magnitude
Stock	Sponsor	Valued from \$50,001 to \$100,000
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued less than \$5,001
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000
Stock	Competitor	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interests, the waivers are not valid.

_____/S/_____
Signature

____4/10/08_____
Date